
Pharmaceuticals · NSE / BSE
Supriya Lifescience is a manufacturer of Active Pharmaceutical Ingredients (APIs), producing 38 APIs across therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergics. Between FY 2017 and FY 2021, it was the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, and one of the largest exporters of Salbutamol Sulphate in FY 2021. The company exports to 86 countries, serving 1,296 customers, including 346 distributors, across Europe, Latin America, Asia, and North America. Its modern manufacturing facility in Maharashtra spans 23,806 sq. m with a reactor capacity of 547 KL/day and seven clean rooms. Supriya Lifescience has acquired an additional 12,551 sq. m plot for expansion and holds regulatory approvals from USFDA, EDQM, TGA-Australia, KFDA-Korea, PMDA-Japan, NMPA-China, and Health Canada for its API exports.
Price Band
₹265 – ₹274
Issue Size
₹700 Cr
Lot Size
54 shares
GMP
+47.5%
Est. Listing
₹404
at current GMP
Subscribed
—
Open
16 Dec 2021
Close
20 Dec 2021
Allotment
23 Dec 2021
Refund
24 Dec 2021
Demat Credit
25 Dec 2021
Listing
28 Dec 2021
Overall Subscription
0.00x
Total Demand
QIB Multiplier
0.00x
Institutions & Funds
NII / HNI
0.00x
High Net-Worth
Retail (RII)
0.00x
Individual Bidders
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| Qualified Institutional (QIB) | 12,773,723 | — | 0.00x |
| Non-Institutional (NII / HNI) | 3,832,117 | — | 0.00x |
| Retail Individual (RII) | 8,941,606 | — | 0.00x |
| Total | 25,547,446 | 0 | 0.00x |
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| Retail (RII) | 165,585 | 165,585 | 1.00x |
| HNIs (10L +) | 1,059 | 1,059 | 1.00x |
| HNIs (2-10L) | 5,069 | 5,069 | 1.00x |
| Total Applications | 171,713 | 171,713 | 1.00x |
Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.
Supriya Lifescience Limited is bringing an initial public offering (IPO) in the Pharmaceuticals sector with an aggregate issue size of ₹700 Crores. The shares are offered at a price band of ₹265 to ₹274 per equity share on NSE and BSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 54 shares (approx. ₹14,796 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Link Intime India Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2021-12-25, while un-allotted funds or UPI block mandates will be released on 2021-12-24.
The latest Grey Market Premium (GMP) for Supriya Lifescience Limited IPO is ₹130 per equity share. Based on the upper price band of ₹265 to ₹274 per equity share, the estimated listing price is ₹404 (+47.5% expected listing gain).
With a lot size of 54 shares and current GMP of ₹130, the expected profit per application lot is approx ₹7,020 (+47.5% gain). Minimum application cost is approx ₹14,796.
The Supriya Lifescience Limited IPO aggregate issue size is ₹700 Crores with an equity price band set at ₹265 to ₹274 per equity share. The retail lot size is 54 shares requiring a minimum capital outlay of approx. ₹14,796.
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 0.00x (Retail: 0.00x, QIB: 0.00x, NII: 0.00x). You can track live multiples directly on our dedicated subscription page.
The basis of allotment will be published on the official registrar portal (Link Intime India Private Limited) and the BSE status verification website on or around 2021-12-23. Investors can verify status using PAN card or application number.
Supriya Lifescience Limited shares are scheduled to list on NSE and BSE on 2021-12-28.